Background: COVID-19 severity is affected by multiple factors and it is theorized that better glycemic control results in lower mortality. Also, the use of glycemic variability through Time In Range (TIR) may be a better indicator of glycemic control.
Objective: To determine the association of glycemic control (ie TIR and HbA1c) during admission with in-hospital mortality among patients with COVID-19, CKD, and T2DM
Methods: A single center retrospective study was conducted on admitted CKD T2DM COVID patients from September 2020 to December 2021. Participants were excluded with mild COVID-19, post kidney transplant, no CBG monitoring, admitted for < 24 hours. A survival analysis was used to determine the association of glycemic control & mortality.
Results: Among 148 patients, 42.0% (n = 63) had in-hospital mortality. Glycemic control within range was achieved in 4.7% (4 out of 85) of the survivor group and 1.6% (1 out of 63) of the non survivor group and no significant difference noted between the two groups (HR 0.41 95% CI 0.06 to 3.03). For HbA1c level on admission, no significant difference between the two groups (HR 1.22 95% CI 0.74 to 2.01).
Conclusion: This study concluded that glycemic control did not show association with in-hospital mortality among CKD T2DM patients with COVID-19 infection. Additionally, HBA1c on admission was not associated with mortality.
N.G.Mangugan: None.
